1. Zhou, M.; Wang, H.; Zeng, X.; Yin, P.; Zhu, J.; Chen, W.; Li, X.; Wang, L.; Wang, L.; Liu, Y.; Liu, J.; Zhang, M.; Qi, J.; Yu, S.; Afshin, A.; Gakidou, E.; Glenn, S.; Krish, V. S.; Miller-Petrie, M. K.; Mountjoy-Venning, W. C.; Mullany, E. C.; Redford, S. B.; Liu, H.; Naghavi, M.; Hay, S. I.; Wang, L.; Murray, C. J. L.; Liang, X., Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2019, 394, (10204), 1145-1158.
2. Mathers, C. D.; Loncar, D., Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3, (11), e442.
3. Hall, G. L.; Irvin, C. G., Using lung function measurements to greater advantage in patients with lung disease: which test and when? Respirology 2014, 19, (6), 780-1.
4. Vestbo, J.; Edwards, L. D.; Scanlon, P. D.; Yates, J. C.; Agusti, A.; Bakke, P.; Calverley, P. M.; Celli, B.; Coxson, H. O.; Crim, C.; Lomas, D. A.; MacNee, W.; Miller, B. E.; Silverman, E. K.; Tal-Singer, R.; Wouters, E.; Rennard, S. I.; Investigators, E., Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011, 365, (13), 1184-92.
5. Dasenbrook, E. C.; Fink, A. K.; Schechter, M. S.; Sanders, D. B.; Millar, S. J.; Pasta, D. J.; Mayer-Hamblett, N., Rapid lung function decline in adults with early-stage cystic fibrosis lung disease. J Cyst Fibros 2020, 19, (4), 527-533.
6. Brumpton, B. M.; Langhammer, A.; Henriksen, A. H.; Camargo, C. A., Jr.; Chen, Y.; Romundstad, P. R.; Mai, X. M., Physical activity and lung function decline in adults with asthma: The HUNT Study. Respirology 2017, 22, (2), 278-283.
7. Mannino, D. M.; Reichert, M. M.; Davis, K. J., Lung function decline and outcomes in an adult population. Am J Respir Crit Care Med 2006, 173, (9), 985-90.
8. Martinez, F. J.; Han, M. K.; Allinson, J. P.; Barr, R. G.; Boucher, R. C.; Calverley, P. M. A.; Celli, B. R.; Christenson, S. A.; Crystal, R. G.; Fageras, M.; Freeman, C. M.; Groenke, L.; Hoffman, E. A.; Kesimer, M.; Kostikas, K.; Paine, R., 3rd; Rafii, S.; Rennard, S. I.; Segal, L. N.; Shaykhiev, R.; Stevenson, C.; Tal-Singer, R.; Vestbo, J.; Woodruff, P. G.; Curtis, J. L.; Wedzicha, J. A., At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2018, 197, (12), 1540-1551.
9. Bartel, D. P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116, (2), 281-97.
10. Boateng, E.; Krauss-Etschmann, S., miRNAs in Lung Development and Diseases. Int J Mol Sci 2020, 21, (8).
11. Wu, K. L.; Tsai, Y. M.; Lien, C. T.; Kuo, P. L.; Hung, A. J., The Roles of MicroRNA in Lung Cancer. Int J Mol Sci 2019, 20, (7).
12. Ellis, K. L.; Cameron, V. A.; Troughton, R. W.; Frampton, C. M.; Ellmers, L. J.; Richards, A. M., Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail 2013, 15, (10), 1138-47.
13. Conickx, G.; Mestdagh, P.; Avila Cobos, F.; Verhamme, F. M.; Maes, T.; Vanaudenaerde, B. M.; Seys, L. J.; Lahousse, L.; Kim, R. Y.; Hsu, A. C.; Wark, P. A.; Hansbro, P. M.; Joos, G. F.; Vandesompele, J.; Bracke, K. R.; Brusselle, G. G., MicroRNA Profiling Reveals a Role for MicroRNA-218-5p in the Pathogenesis of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2017, 195, (1), 43-56.
14. Zhang, J.; Xu, Z.; Kong, L.; Gao, H.; Zhang, Y.; Zheng, Y.; Wan, Y., miRNA-486-5p Promotes COPD Progression by Targeting HAT1 to Regulate the TLR4-Triggered Inflammatory Response of Alveolar Macrophages. Int J Chron Obstruct Pulmon Dis 2020, 15, 2991-3001.
15. Pandit, K. V.; Corcoran, D.; Yousef, H.; Yarlagadda, M.; Tzouvelekis, A.; Gibson, K. F.; Konishi, K.; Yousem, S. A.; Singh, M.; Handley, D.; Richards, T.; Selman, M.; Watkins, S. C.; Pardo, A.; Ben-Yehudah, A.; Bouros, D.; Eickelberg, O.; Ray, P.; Benos, P. V.; Kaminski, N., Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010, 182, (2), 220-9.
16. Pattarayan, D.; Thimmulappa, R. K.; Ravikumar, V.; Rajasekaran, S., Diagnostic Potential of Extracellular MicroRNA in Respiratory Diseases. Clin Rev Allergy Immunol 2018, 54, (3), 480-492.
17. Zhou, T.; Yu, Q.; Sun, C.; Wang, Y.; Zhong, Y.; Wang, G., A pilot study of blood microRNAs and lung function in young healthy adults with fine particulate matter exposure. J Thorac Dis 2018, 10, (12), 7073-7080.
18. Zhou, Y.; Sun, H.; Xie, J.; Song, Y.; Liu, Y.; Huang, X.; Zhou, T.; Rong, Y.; Wu, T.; Yuan, J.; Chen, W., Urinary Polycyclic Aromatic Hydrocarbon Metabolites and Altered Lung Function in Wuhan, China. Am J Respir Crit Care Med 2016, 193, (8), 835-46.
19. Wang, B.; Yang, S.; Guo, Y.; Wan, Y.; Qiu, W.; Cheng, M.; Wang, X.; Yang, M.; Yu, Y.; Ma, J.; Zhou, Y.; Li, W.; Gan, S.; Shi, T.; Yuan, J.; Chen, W., Association of urinary dimethylformamide metabolite with lung function decline: The potential mediating role of systematic inflammation estimated by C-reactive protein. Sci Total Environ 2020, 726, 138604.
20. Fawzy, M. S.; Hussein, M. H.; Abdelaziz, E. Z.; Yamany, H. A.; Ismail, H. M.; Toraih, E. A., Association of MicroRNA-196a2 Variant with Response to Short-Acting beta2-Agonist in COPD: An Egyptian Pilot Study. PLoS One 2016, 11, (4), e0152834.
21. Huang, X.; Zhu, Z.; Guo, X.; Kong, X., The roles of microRNAs in the pathogenesis of chronic obstructive pulmonary disease. Int Immunopharmacol 2019, 67, 335-347.
22. Wang, M.; Huang, Y.; Liang, Z.; Liu, D.; Lu, Y.; Dai, Y.; Feng, G.; Wang, C., Plasma miRNAs might be promising biomarkers of chronic obstructive pulmonary disease. Clin Respir J 2016, 10, (1), 104-11.
23. Xie, L.; Wu, M.; Lin, H.; Liu, C.; Yang, H.; Zhan, J.; Sun, S., An increased ratio of serum miR-21 to miR-181a levels is associated with the early pathogenic process of chronic obstructive pulmonary disease in asymptomatic heavy smokers. Mol Biosyst 2014, 10, (5), 1072-81.
24. Wang, R.; Xu, J.; Liu, H.; Zhao, Z., Peripheral leukocyte microRNAs as novel biomarkers for COPD. Int J Chron Obstruct Pulmon Dis 2017, 12, 1101-1112.
25. Akbas, F.; Coskunpinar, E.; Aynaci, E.; Oltulu, Y. M.; Yildiz, P., Analysis of serum micro-RNAs as potential biomarker in chronic obstructive pulmonary disease. Exp Lung Res 2012, 38, (6), 286-94.
26. Soeda, S.; Ohyashiki, J. H.; Ohtsuki, K.; Umezu, T.; Setoguchi, Y.; Ohyashiki, K., Clinical relevance of plasma miR-106b levels in patients with chronic obstructive pulmonary disease. Int J Mol Med 2013, 31, (3), 533-9.
27. Maes, T.; Cobos, F. A.; Schleich, F.; Sorbello, V.; Henket, M.; De Preter, K.; Bracke, K. R.; Conickx, G.; Mesnil, C.; Vandesompele, J.; Lahousse, L.; Bureau, F.; Mestdagh, P.; Joos, G. F.; Ricciardolo, F. L.; Brusselle, G. G.; Louis, R., Asthma inflammatory phenotypes show differential microRNA expression in sputum. J Allergy Clin Immunol 2016, 137, (5), 1433-46.
28. Shi, W.; Lu, Y.; Gong, R.; Sun, J. J.; Liu, G., Serum miR-629 is a novel molecular marker for diagnosis and the prognosis of pancreatic cancer. Eur Rev Med Pharmacol Sci 2018, 22, (16), 5187-5193.
29. Yue, P. J.; Sun, Y. Y.; Li, Y. H.; Xu, Z. M.; Fu, W. N., MYCT1 inhibits the EMT and migration of laryngeal cancer cells via the SP1/miR-629-3p/ESRP2 pathway. Cell Signal 2020, 74, 109709.
30. Zhang, X.; Luo, P.; Jing, W.; Zhou, H.; Liang, C.; Tu, J., circSMAD2 inhibits the epithelial-mesenchymal transition by targeting miR-629 in hepatocellular carcinoma. Onco Targets Ther 2018, 11, 2853-2863.
31. Jingushi, K.; Ueda, Y.; Kitae, K.; Hase, H.; Egawa, H.; Ohshio, I.; Kawakami, R.; Kashiwagi, Y.; Tsukada, Y.; Kobayashi, T.; Nakata, W.; Fujita, K.; Uemura, M.; Nonomura, N.; Tsujikawa, K., miR-629 Targets TRIM33 to Promote TGFbeta/Smad Signaling and Metastatic Phenotypes in ccRCC. Mol Cancer Res 2015, 13, (3), 565-74.
32. Zhu, L.; Chen, Y.; Liu, J.; Nie, K.; Xiao, Y.; Yu, H., MicroRNA-629 promotes the tumorigenesis of non-small-cell lung cancer by targeting FOXO1 and activating PI3K/AKT pathway. Cancer Biomark 2020, 29, (3), 347-357.
33. Ji, X.; Wu, B.; Fan, J.; Han, R.; Luo, C.; Wang, T.; Yang, J.; Han, L.; Zhu, B.; Wei, D.; Chen, J.; Ni, C., The Anti-fibrotic Effects and Mechanisms of MicroRNA-486-5p in Pulmonary Fibrosis. Sci Rep 2015, 5, 14131.
34. Chen, T.; Zhu, J.; Cai, T.; Du, W.; Zhang, Y.; Zhu, Q.; Liu, Z.; Huang, J. A., Suppression of non-small cell lung cancer migration and invasion by hsa-miR-486-5p via the TGF-beta/SMAD2 signaling pathway. J Cancer 2019, 10, (24), 6014-6024.
35. He, Y.; Liu, J.; Wang, Y.; Zhu, X.; Fan, Z.; Li, C.; Yin, H.; Liu, Y., Role of miR-486-5p in regulating renal cell carcinoma cell proliferation and apoptosis via TGF-beta-activated kinase 1. J Cell Biochem 2019, 120, (3), 2954-2963.
36. Li, J.; Zhou, Q.; Liang, Y.; Pan, W.; Bei, Y.; Zhang, Y.; Wang, J.; Jiao, Z., miR-486 inhibits PM2.5-induced apoptosis and oxidative stress in human lung alveolar epithelial A549 cells. Ann Transl Med 2018, 6, (11), 209.
37. Chai, X.; Si, H.; Song, J.; Chong, Y.; Wang, J.; Zhao, G., miR-486-5p Inhibits Inflammatory Response, Matrix Degradation and Apoptosis of Nucleus Pulposus Cells through Directly Targeting FOXO1 in Intervertebral Disc Degeneration. Cell Physiol Biochem 2019, 52, (1), 109-118.
38. Wang, C. J.; Li, B. B.; Tan, Y. J.; Zhang, G. M.; Cheng, G. L.; Ren, Y. S., MicroRNA-31/184 is involved in transforming growth factor-beta-induced apoptosis in A549 human alveolar adenocarcinoma cells. Life Sci 2020, 242, 117205.
39. Zanchi, C.; Macconi, D.; Trionfini, P.; Tomasoni, S.; Rottoli, D.; Locatelli, M.; Rudnicki, M.; Vandesompele, J.; Mestdagh, P.; Remuzzi, G.; Benigni, A.; Zoja, C., MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy. Diabetologia 2017, 60, (6), 1114-1125.
40. Konigshoff, M.; Eickelberg, O., WNT signaling in lung disease: a failure or a regeneration signal? Am J Respir Cell Mol Biol 2010, 42, (1), 21-31.
41. Seiler, F.; Hellberg, J.; Lepper, P. M.; Kamyschnikow, A.; Herr, C.; Bischoff, M.; Langer, F.; Schafers, H. J.; Lammert, F.; Menger, M. D.; Bals, R.; Beisswenger, C., FOXO transcription factors regulate innate immune mechanisms in respiratory epithelial cells. J Immunol 2013, 190, (4), 1603-13.
42. Kim, E. K.; Choi, E. J., Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 2010, 1802, (4), 396-405.
43. Lv, W. P.; Li, M. X.; Wang, L., Peroxiredoxin 1 inhibits lipopolysaccharide-induced oxidative stress in lung tissue by regulating P38/JNK signaling pathway. Eur Rev Med Pharmacol Sci 2017, 21, (8), 1876-1883.
44. Balakrishna, S.; Song, W.; Achanta, S.; Doran, S. F.; Liu, B.; Kaelberer, M. M.; Yu, Z.; Sui, A.; Cheung, M.; Leishman, E.; Eidam, H. S.; Ye, G.; Willette, R. N.; Thorneloe, K. S.; Bradshaw, H. B.; Matalon, S.; Jordt, S. E., TRPV4 inhibition counteracts edema and inflammation and improves pulmonary function and oxygen saturation in chemically induced acute lung injury. Am J Physiol Lung Cell Mol Physiol 2014, 307, (2), L158-72.
45. Saito, A.; Horie, M.; Nagase, T., TGF-beta Signaling in Lung Health and Disease. Int J Mol Sci 2018, 19, (8).
46. Ludwig, N.; Leidinger, P.; Becker, K.; Backes, C.; Fehlmann, T.; Pallasch, C.; Rheinheimer, S.; Meder, B.; Stahler, C.; Meese, E.; Keller, A., Distribution of miRNA expression across human tissues. Nucleic Acids Res 2016, 44, (8), 3865-77.